| Identification | Back Directory | [Name]
(Z)-N'-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotiniMidaMide | [CAS]
66611-37-8 | [Synonyms]
CS-2406
BGP-15 HCl
BGP-15 2HCl
BGP 15;BGP15
BGP-15 dihydrochloride
(Z)-N'-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotiniMidaMide
N-(2-Hydroxy-3-(piperidin-1-yl)propoxy)-nicotinimidamide dihydrochloride
(Z)-N'-(2-Hydroxy-3-(piperidin-1-yl)propoxy)nicotiniMidaMide dihydrochloride | [Molecular Formula]
C14H22N4O2 | [MDL Number]
MFCD21603901 | [MOL File]
66611-37-8.mol | [Molecular Weight]
278.35 |
| Chemical Properties | Back Directory | [storage temp. ]
-20°C | [solubility ]
Soluble in Water (70 mg/ml) | [form ]
solid | [color ]
Off-white | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in water may be stored at room temperature for up to 1 month. |
| Hazard Information | Back Directory | [Description]
BGP-15 (66611-37-8) is a cellular protectant operating by several mechanisms. It is an insulin sensitizer1, HSP72 activator2, PARP inhibitor and ROS and lipid peroxidation reducer3. It protects mitochondria in acetaminophen-induced liver injury4 as well as LPS-induced destabilization5 and activates mitochondrial fusion6. Displays protective effects in heart failure7 and traumatic brain injury8 in animal models. | [Uses]
BGP 15 is a calcipotriene-based vitamin D3 analog that inhibits poly(ADP-ribose) polymerasesis (PARP), a class of enzymes that regulate DNA repair and apoptosis (1). BGP 15 is also a cardioprotective agent (2). Also, BPG 15 improves mitochondrial function, protects neurons from dying in vitro and in vivo, and promotes cardiac innervation in vivo. | [in vitro]
previous study showed that bgp-15 at 200 μm could prevent the imatinib-induced oxidative damages, attenuate the depletion of high-energy phosphates, alter the signaling effect of imatinib by preventing p38 map kinase and jnk activation, and also induce the akt and gsk-3β phosphorylation [1]. | [in vivo]
in-vivo study indicated that bgp-15 improved cardiac function and reduced arrhythmic episodes in two hf and af mouse models. in these models, bgp-15 was associated with increased phosphorylation of igf1r. moreover, cardiac-specific igf1r transgenic overexpression in mice recapitulated the protection caused by bgp-15. the authors further demonstrated that bgp-15 with igf1r could provide protection independent of phosphoinositide 3-kinase-akt and heat-shock protein 70 [2]. | [storage]
Store at -20°C | [References]
Peto et al. (2020), Pharmacological Overview of the BGP-15 Chemical Agent as a New Drug Candidate for the Treatment of Symptoms of Metabolic Syndrome; Molecules 25 429
Henstridge et al. (2014), Activating HSP72 in rodent skeletal muscle increases mitochondrial number and oxidative capacity and decreases insulin resistance; Diabetes 63 1881
Szabados et al. (2000), BGP-15, a nicotinic amidoxime derivative protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase; Biochem. Pharmacol. 59 937
Sarnyai et al. (2020), BGP-15 Protects Mitochondria in Acute Acetaminophen Overdose Induced Liver Injury; Pathol. Oncol. Res. 26 1797
Sumegi et al. (2017), BGP-15 Protects against Oxidative Stress- or Lipopolysaccharide-Induced Mitochondrial Destabilization and Reduces Mitochondrial Production of Reactive Oxygen Species; PLos One 12 e0169372
Szabo et al. (2018), Activation of mitochondrial fusion provides a new treatment for mitochondria-related diseases; Biochem. Pharmacol. 150 86
Sapra et al. (2014), The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice; Nat. Commun. 5 5705
Eroglu et al. (2014), Therapeutic inducers of the HSP70/HSP110 protect mice against traumatic brain injury; J. Neurochem. 130 626 |
|
| Company Name: |
SynAsst Chemical.
|
| Tel: |
021-60343070 |
| Website: |
www.is0513.com/ShowSupplierProductsList15848/0.htm |
|